Aerosol formulations of salmeterol xinafoate
US6613307B1 · kind B1 · utility
Assignee
Inventor
Key dates
| Filing date | Oct 5, 2000 |
| Grant date | Sep 2, 2003 |
| Priority date | — |
| Expiry date | Oct 5, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P11/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to formulations comprising particulate products which may be prepared by methods and apparatus using supercritical fluids. More particularly, the invention relates to formulations comprising certain crystalline forms of 4-hydroxy-&agr;1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol (salmeterol) 1-hydroxy-2-naphthalenecarboxylate (xinafoate). Accordingly, the present invention provides an aerosol pharmaceutical formulation comprising salmeterol xinafoate with a controlled particle size, shape and morphology, and a fluorocarbon, hydrogen-containing fluorocarbon or hydrogen-containing chlorofluorocarbon propellant.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.